Frequency Therapeutics Stock
Small, molecular progenitor cells drugs
About Frequency Therapeutics Stock
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. The lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.
Funding History
| April 2017 | $32.0M |
|---|---|
| May 2018 | $2.0M |
| January 2019 | $42.0M |
Management
Co-founder, President and Chief Executive Officer
David L. Lucchino
Co-founder and Vice President, Biology and Regenerative Medicine
Will McLean
Co-Founder, Co-chair of Scientific Advisory Board
Jeff Karp
Chief Operating Officer
Michael Jirousek
Co-founder and Chief Scientific Officer
Chris Loose
Chief Medical Officer
Peter Weber
Senior Vice President, Drug Development and Technical Operations
Raj Manchanda
Press
TechCrunch - Jul, 28 2017
TechCrunch - Feb, 22 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Frequency Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
